Related introduction of Dawnzera (donidalorsen): What kind of medicine is it used to treat?

Dawnzera (donidalorsen) is a new class of medicine designed to prevent the onset of hereditary angioedema (HAE) in adults and children 12 years and older. HAE is a rare and potentially life-threatening genetic disease. Its occurrence is mainly related to mutations in the SERPING1 gene, which leads to the deficiency or dysfunction of C1 esterase inhibitor (C1-INH). C1-INH deficiency leads to overproduction of kallikrein in the plasma, which in turn causes overproduction of bradykinin. Bradykinin is a powerful vasodilator that can trigger a sharp increase in vascular permeability, leading to edema in different parts of the body, manifesting as severe swelling attacks, which has a great impact on the patient's quality of life.

The active ingredient of Dawnzera, donidalorsen, is a prekallikrein-directed antisense oligonucleotide, which mainly reduces the production of bradykinin by targeting the expression of prekallikrein (PKK). PKK is the zymogen of plasma kallikrein, and its excessive release is directly related to the onset of HAE. By reducing the level of PKK, Dawnzera can effectively control the production of bradykinin, thereby preventing HAE attacks and helping patients avoid various serious complications caused by edema.

Dawnzera is administered by subcutaneous injection every 4 weeks, and patients can self-inject under the guidance of a doctor. This method of administration is not only convenient for patients, but can also effectively maintain the concentration of the drug in the body, thereby achieving a sustained preventive effect.

However, there are warnings and precautions when using Dawnzera. For example, hypersensitivity reactions, including anaphylaxis, may occur. In addition, common adverse reactions with an incidence rate greater than 5% include injection site reactions, upper respiratory tract infections, urinary tract infections, and abdominal discomfort. Therefore, when using this drug, patients should follow their doctor's recommendations and conduct regular follow-up visits to ensure medication safety and maximum efficacy.

BecauseDawnzera (donidalorsen) has been on the market for a short time, and its price is not yet known.

Reference materials:https://www.drugs.com/dawnzera.html